Berapa harga Aardvark Therapeutics, Inc. Common Stock (AARD)

Harga Aardvark Therapeutics, Inc. Common Stock (AARD) adalah $7.22

Apa kapitalisasi pasar Aardvark Therapeutics, Inc. Common Stock (AARD)

Kapitalisasi pasar Aardvark Therapeutics, Inc. Common Stock (AARD) adalah $158.03M

Aardvark Therapeutics, Inc. Common Stock (AARD) Rasio P/S

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Tahun	Rasio P/S	Mengubah
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Rasio P/S

Mengubah

Tidak cukup data untuk tanggal yang disediakan.

Perusahaan	Rasio P/S	Perbedaan Rasio P/S	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
Moderna, Inc. MRNA.US	11.28	-	US
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH

Perusahaan

Rasio P/S

Perbedaan Rasio P/S

Negara